New daily pill aims to tackle Hard-to-Treat lymphoma
NCT ID NCT07658352
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental daily pill called HP-002 in people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. It includes several lymphoma subtypes such as CLL/SLL, MCL, MZL, DLBCL, FL, WM, and PCNSL.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HP-002 (a daily oral drug)
- What this could lead to
- If successful, HP-002 could offer a new treatment option for people with certain types of lymphoma that have not responded to other therapies.
- What could go wrong
- This is an early, first-in-human study, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smarter steroid schedule might tame Chemotherapy's blood sugar spike
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- New drug combo aims to tackle Hard-to-Treat lymphoma
- New drug candidate SHR-3079 targets Hard-to-Treat lymphoma
- Military study probes Toxins' role in lymphoma